SER Serina Therapeutics, Inc.

BEARISH Impact: 7/10 EFFECT
Horizon weeks Filed Jun 4, 2026 Processed 10d 22h ago SEC 9999999995-26-001872
IPO/offering going effective
Latest settled — T+1d
SER ▲ +1.08% at T+1d
SHORT call ✗ call lost -1.08% · α vs SPY -3.67% · entry $1.86 → $1.88
Next anchor: T+5d due 4d ago
Last close $1.84 (close Jun 12) · +1.08% from $1.86 entry (call sign-flipped)
Entry anchored
Jun 4, 2026
via day open
T+1d
+1.08%
call -1.08% · α -3.67%
$1.88
settled 10d ago
T+5d
call — · α —
due 4d ago
T+20d
call — · α —
in 18d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

The SEC declared effective Serina Therapeutics' S-3 shelf registration (File No. 333-296166) on June 3, 2026. This shelf, filed 13 days ago, registers up to 16,450,442 shares of common stock for resale by selling stockholders, stemming from a $21.2M PIPE in March/April 2026. With ~15M shares outstanding, potential dilution exceeds 100%, and the company disclosed substantial doubt about its ability to continue as a going concern in its most recent 10-Q.

Actionable Insight

The shelf going effective opens the door for selling stockholders, including insiders, to exit their positions. With the company burning cash and expressing going-concern doubt, expect persistent overhang and likely further price pressure. Monitor for a prospectus supplement indicating an actual takedown.

Key Facts

  • Effectiveness date: June 3, 2026 for S-3 File No. 333-296166
  • Registration covers up to 16,450,442 shares for resale by selling stockholders
  • Shares originate from a $21.2M PIPE completed in March/April 2026
  • Approximately 14,997,505 shares currently outstanding — potential dilution exceeds 100%
  • Company disclosed substantial doubt about going concern in its most recent 10-Q (net loss -$6.9M in Q1 2026 vs -$4.8M in Q1 2025)
  • Selling stockholders include insider Dr. Gregory H. Bailey

Financial Impact

Potential dilution of over 100% on current ~15M shares outstanding via up to 16.45M registered shares for resale

dilutionshare price

Risk Factors

  • Massive dilution overhang with >100% potential share count increase
  • Insider selling pressure from PIPE participants including Dr. Gregory H. Bailey
  • Going-concern risk highlighted in recent 10-Q with widening net losses
  • Low market cap ($27M) amplifies impact of any secondary sales

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (6 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001872
Document: 9999999995-26-001872-index.html9999999995-26-001872
Document: 9999999995-26-001872.txt9999999995-26-001872
6 reports for SER
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for SER — sortable, filterable
Type Now
Jun 4, 2026
11d ago
EFFECT
BEARISH ★ 7/10
$1.86 $1.88▼ −1.08%▼ −3.67%$1.84 (+1.08%)
May 26, 2026
19d ago
Insider Cluster
MIXED ★ 5/10
$1.80 $1.95▲ +8.33%▲ +7.78%$1.84 (+2.22%)
May 26, 2026
19d ago
Insider Cluster
BEARISH ★ 5/10
$1.80 $1.95▼ −8.33%▼ −7.78%$1.84 (−2.22%)
May 22, 2026
23d ago
S-3
BEARISH ★ 7/10
$1.92 $1.86▲ +3.13%▲ +3.08%$1.84 (+4.17%)
Mar 27, 2026
11w ago
10-K/A
NEUTRAL ★ 2/10
$2.27 $1.80▼ −20.70%▼ −20.35%$1.84 (−18.94%)
Mar 25, 2026
11w ago
Press Release
MIXED ★ 7/10
$2.61 $2.27▼ −13.03%▼ −11.35%$1.84 (−29.50%)
Showing 6 of 6

US Market Status

Market Closed — Opens in 4h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access